PURPOSE: To evaluate anal cancer uptake of F-18 fluorodeoxyglucose (FDG) measured as the maximum standardized uptake value (SUV(max)) by positron emission tomography (PET) and its correlation with prognostic factors. PATIENTS AND METHODS: The study population consisted of 77 patients with stages 0-IIIB anal cancer who underwent pre-treatment FDG-PET. Tumor histology included 65 squamous cell, 11 basaloid, and 1 small cell cancers. SUV(max) and sites of lymph node metastasis were recorded. We analyzed the association between SUV(max) and prognostic factors. RESULTS: The mean SUV(max) was 10.0 (range 1.0-43.1). The stage distribution included: 2 stage 0, 7 stage I, 49 stage II, 10 stage IIIA, 9 stage IIIB. SUV(max) and clinical tumor size were not associated (R(2)=0.338). Histology did not significantly influence SUV(max) (mean SUV(max) 10.0 for squamous versus 9.90 for basaloid). Higher SUV(max) was associated with an increased risk of nodal metastasis at diagnosis (p<0.0001). Higher SUV(max) was associated with worse disease-free survival (p=0.05). Patients with high anal tumor SUV(max) at diagnosis were at an increased risk of persistent or recurrent disease on post-therapy FDG-PET performed less than 4months after completing therapy (p=0.0402). CONCLUSIONS: SUV(max) is a valuable biomarker of anal cancer prognosis, predicting increased risk of lymph node metastasis and worse disease-free survival. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
PURPOSE: To evaluate anal cancer uptake of F-18fluorodeoxyglucose (FDG) measured as the maximum standardized uptake value (SUV(max)) by positron emission tomography (PET) and its correlation with prognostic factors. PATIENTS AND METHODS: The study population consisted of 77 patients with stages 0-IIIB anal cancer who underwent pre-treatment FDG-PET. Tumor histology included 65 squamous cell, 11 basaloid, and 1 small cell cancers. SUV(max) and sites of lymph node metastasis were recorded. We analyzed the association between SUV(max) and prognostic factors. RESULTS: The mean SUV(max) was 10.0 (range 1.0-43.1). The stage distribution included: 2 stage 0, 7 stage I, 49 stage II, 10 stage IIIA, 9 stage IIIB. SUV(max) and clinical tumor size were not associated (R(2)=0.338). Histology did not significantly influence SUV(max) (mean SUV(max) 10.0 for squamous versus 9.90 for basaloid). Higher SUV(max) was associated with an increased risk of nodal metastasis at diagnosis (p<0.0001). Higher SUV(max) was associated with worse disease-free survival (p=0.05). Patients with high anal tumor SUV(max) at diagnosis were at an increased risk of persistent or recurrent disease on post-therapy FDG-PET performed less than 4months after completing therapy (p=0.0402). CONCLUSIONS: SUV(max) is a valuable biomarker of anal cancer prognosis, predicting increased risk of lymph node metastasis and worse disease-free survival. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
Authors: F L Day; E Link; S Ngan; T Leong; K Moodie; C Lynch; M Michael; E de Winton; A Hogg; R J Hicks; A Heriot Journal: Br J Cancer Date: 2011-07-26 Impact factor: 7.640
Authors: Ramin Sadeghi; Sara Harsini; Mohammad Ali Qodsi Rad; Vahid Reza Dabbagh; Giorgio Treglia Journal: Contrast Media Mol Imaging Date: 2018-12-04 Impact factor: 3.161
Authors: P J Brown; J Zhong; R Frood; S Currie; A Gilbert; A L Appelt; D Sebag-Montefiore; A Scarsbrook Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-04 Impact factor: 9.236
Authors: Matthew S Susko; Ann A Lazar; Chia-Ching Jackie Wang; Katherine Van Loon; Mary Feng; Tom A Hope; Spencer Behr; Mekhail Anwar Journal: PLoS One Date: 2021-02-04 Impact factor: 3.240